Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141
Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Robert L. Ferris(University of Pittsburgh), J. Guigay(Centre Antoine Lacassagne), Makoto Tahara(National Cancer Center Hospital East), Francis P. Worden(Georgetown University), Mark Lynch(Fluidigm (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Tamara Rordorf(Institut Gustave Roussy), Naomi Kiyota(Kobe University Hospital), Justin Kopit(Gdańsk Medical University), Nabil F. Saba(Emory University), Lisa Licitra(University of Milan), Lara Carmen Iglesias Docampo(Institut Gustave Roussy), James W. Shaw(University of Illinois Chicago), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Manish Monga(Institut Gustave Roussy), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), William J. Geese(Institut Gustave Roussy), Mark Schactman(British Heart Foundation), Caroline Even(Institut Gustave Roussy), Stefan Kasper(Essen University Hospital)
Cited by 36
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k